Introduction
MicroRNAs (miRNAs) are small, noncoding RNAs that regulate gene expression posttranscriptionally. MiRNAs have been implicated in neurodegenerative diseases, such as Alzheimer's disease (AD) [1] [2] [3] [4] . MiRNAs are expressed in virtually all known mammalian cells and can be found in body fluids including serum, cerebrospinal fluid (CSF), saliva, urine, and breast milk [5] , providing a potential opportunity to monitor disease presence and severity. Studies have shown that miRNAs in serum and plasma are stable at room temperature for several days and even resistant to RNase treatment [6] . Furthermore, they are also easier to detect and quantify Electronic supplementary material The online version of this article (doi:10.1007/s12035-016-0316-2) contains supplementary material, which is available to authorized users. compared to many protein biomarkers [7] . Thus, biofluid miRNAs are good candidates for biomarkers.
Despite extensive studies, no miRNA has been firmly established as a clinically relevant biomarker. Challenges include the complexity of the pathophysiological conditions (various stages of disease and comorbid pathologies) and also probably heterogeneous human cohorts [8, 9] . This is particularly true for neurodegenerative diseases. Furthermore, preanalytical and analytical factors such as sampling methods, specimen storage, RNA isolation and detection platform, and data normalization all contribute to the mixed outcomes of the analysis [10] [11] [12] .
CSF provides a special context for biomarkers. Already used as an AD biomarker detecting Aβ, tau, and other analytes, CSF can be obtained via routine lumbar puncture. This clear proteinaceous fluid is normally in direct contact with the brain after being produced in the choroid plexus, which exchanges chemicals, proteins, electrolytes, and other molecules with the blood stream. Thus, it is a critical context for searching biomarkers in association with CNS diseases.
Prior studies have analyzed CSF miRNA expression in association with CNS diseases (see for example [13] [14] [15] [16] [17] [18] [19] ). These studies employed various isolation and detection methods, mostly array and deep sequencing-based profiling. Prior studies generated valuable information in searching for reliable biomarkers. However, contradictory results were also reported possibly because of biological complexity and the various study designs and methodological factors. Furthermore, array-and sequencing-based analysis generally have poorer sensitivity and higher variability for low-quantity RNA inputs, which are typical in clinic-derived CSF samples.
Here, we describe a custom-made miRNA RT-qPCR panel that can overcome some of the aforementioned shortcomings in CSF miRNA analysis. The goal was to produce a relatively economic platform that includes miRNAs known to be present in CSF and include those miRNAs that previously were implicated as possible biomarkers. We also used this panel to test whether the miRNA profile of CSF more closely resembles RNA isolated from blood, the choroid plexus, or brain tissues derived from the University of Kentucky AD Center (UK-ADC) biobank.
Materials and Methods
Human Cerebrospinal Fluid, Brain Tissues, and Blood Samples Human CSF and tissues used in this work were obtained from the UK-ADC biobank and analyzed in compliance with University of Kentucky Institutional Review board protocol. Clinical lumbar puncture-derived CSF, blood samples, and snap-frozen brain tissues from individuals obtained at autopsy, as described previously [20, 21] , were coded anonymously.
RNA Isolation from Brain Tissues and Blood
Total RNA was extracted from human tissues and blood samples using TRIzol LS reagent (Thermo Fisher Scientific) following the modified procedure described previously [3, 22, 23] . The RNA concentrations and purity were determined using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Thermo Fisher Scientific).
Testing CSF RNA Isolation Methods
For the study of RNA isolation technical parameters, ten lumbar puncture-harvested CSF samples were mixed and spun at 3000 × g for 5 min. Aliquots of 200 μl supernatant from the mixed sample were used for each RNA isolation procedure. Four replicates were evaluated for each method. Total RNA was extracted and compared using commercially available kits: MagMAX™ mirVana™ Total RNA Isolation Kit (Thermo Fisher Scientific), miRCURY™ RNA Isolation Kit-Biofluids (Exiqon), miRNeasy Serum/Plasma Kit (QIAGEN), NucleoSpin miRNA Plasma (MACHEREY-NAGEL), PureLink™ RNA Mini Kit (Thermo Fisher Scientific), and TRIzol LS reagent (Thermo Fisher Scientific). RNA isolations were carried out following manufacturers' instructions except for TRIzol LS reagent which was done exactly as described previously [3, 22, 23] . RNA isolation experiments were performed with or without nucleic acid carriers, glycogen, and bacteriophage MS2 RNA (both from Roche). RNA was eluted or dissolved with 30 μl of nuclease-free water containing RNAsin (0.5 U/μl, Promega). After a preliminary comparison by single-tube TaqMan® miRNA assays (data not shown), three kits including miRCURY™ RNA Isolation Kit-Biofluids, miRNeasy Serum/Plasma Kit, and TRIzol LS reagent were selected for further assessments by miR-15/107 TaqMan® Low-Density Array (TLDA) analysis [24] .
CSF miRNA Profiling Using TaqMan® Array Human MicroRNA A+B Cards Set v3.0
Clinical CSF samples were collected as described above from additional four controls and four AD patients and the RNA subjected to TaqMan® Array analysis using Human MicroRNA A+B Cards Set v3.0 (Life Technologies). CSF RNA was isolated using Exiqon's miRCURY™ RNA Isolation Kit (Biofluids) following manufacturer's protocol. Briefly, 200 μl of CSF was transferred to a fresh tube after centrifuge at 3000 g for 5 min; 60 μl of Lysis Solution BF was added to the supernatant following a 5-s vortex. After a 3-min incubation, 1 μg of bacteriophage MS2 RNA (carrier, Roche) and 3.5 μl of Cel-miR-39-3p (spike-in RNA, QIAGEN) at 1.6 × 10 8 copies/μl was added to the mixture. Protein Precipitation Solution BF (20 μl) was added, vortex, incubated for 1 min, and centrifuged. The clear supernatant was transferred to a fresh collection tube with addition of 270 μl isopropanol and mixed. Column binding, washing, and drying were conducted as instructed by the protocol, and RNA was eluted with 30 μl of nuclease-free water containing 0.5 U/μl RNAsin (Promega). Next, equal volume of total CSF RNA (3 μl) was reverse transcribed using the TaqMan® MicroRNA Reverse Transcription Kit (Life Technologies) with Megaplex™ Primer Pools, Human Pool A and B, respectively (Life Technologies). The resulting complementary DNA (cDNA) was preamplified using corresponding Human Pool A or B Megaplex™ PreAmp Primers (Life Technologies) before running the qPCR Array. qPCR was carried out on the ViiA™ 7 Real-Time PCR System and quantitative PCR cycle (Cq) was determined using ViiA 7 RUO software (Life Technologies) with automatic baseline and a fixed threshold set at 0.15.
TaqMan® Low-Density Array (TLDA) Analysis
Two separate sets of custom-developed TLDA cards were used in the study: miR-15/107 TLDA cards and CSFmiRNA TLDA cards. MiR-15/107 TLDA cards have been described in detail previously [24] . The CSF-miRNA TLDA card incorporated a combination of miRNAs related to CSF and neurodegenerative diseases and the miRNA selection was discussed in BResults.^Standard manufacturer's protocol was followed for all TLDA cards. Briefly, 3 μl of CSF RNA or tissue RNA (at 10 ng/μl) was reverse transcribed using TaqMan® MicroRNA Reverse Transcription Kit (Life Technologies) with pooled specific RT primers for each panel. An aliquot of RT product was then preamplified using TaqMan® PreAmp Master Mix (Life Technologies) with pooled preamplification primers (Life Technologies). RT products with or without preamplification were served as templates. Premixed template and TaqMan® Universal PCR Master Mix (No AmpErase UNG, Life Technologies) were transferred to each port of TLDA cards and loaded to each well by spinning the cards in a centrifuge according to the manufacturer's instructions. qPCR was performed using ViiA™ 7 Real-Time PCR System (Life Technologies).
TaqMan® Single-Tube RT-qPCR for Individual miRNAs Individual miRNA and spike-in Cel-miR-39 were subjected to single-tube TaqMan® RT-qPCR assay (LifeTechnologies) according to the manufacturer's instructions. Equal volume of CSF RNA (3 μl) for reverse transcription and qPCR was performed in triplicate.
Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) was followed throughout all the RT-qPCR procedure [25] .
Data and Statistical Analysis
Raw PCR Cq values from custom or inventory array cards were first determined using ViiA 7 RUO software (Life Technologies) with automatic baseline and threshold set at 0.15. Data that failed QC, including those such as bad passive reference signal and failed in exponential algorithm and thresholding algorithm (amplification too early or too late, low amplification or no amplification), were treated as undetectable in the analysis. Outliers such as a data point that is much higher or much lower in Cq among replicates in the data set was also examined manually, and an amplification curve that was abnormal (i.e., flat curve which resulted in low Cq) was also treated as undetectable. ) of the datasets from customized CSF panel and inventory array cards was obtained using linear regression function.
Welch's two-sample t test was used to evaluate the difference of the mean and total qPCR array Cq data between the control and AD groups. To determine the differential expression pattern between CSF and tissues, array data were evaluated using an unpaired Student's t test. Hierarchical clustering based on the similarity of miRNA expression patterns was calculated using Pearson's distance-Average Linkage. Benjamini-Hochberg tests were used to control false discovery rate (FDR). p value that is less than 0.05 was considered as statistically significant.
Correlation coefficient (R 2 ) of miRNA expression pattern between CSF and each individual tissue group was obtained using linear regression function, and evaluation of correlations between CSF and various nonindependent tissues was done using confidence intervals according to the method described by Zou [27] .
Results

Empirical Evaluation of CSF RNA Isolation Methods
Isolating quality RNA is a critical first step in studying CSF miRNA. The three most effective kits in our hands were as follows: Exiqon's miRCURY™ RNA Isolation Kit- ) of the two data sets calculated. A representative plot from each method was shown. RNA isolations within each method (a) were highly consistent, with slightly higher variance between the different isolation methods (b) with variance being greater at low-quantity (high-Cq) miRNAs [24] to assess the quantity and quality of CSF RNA isolations. Figure 1 illustrates the procedure used in evaluating CSF RNA isolation. RNA quantity and quality were defined by the following standards: (1) low quantification cycle (Cq); (2) high ΔCq above the background; (3) low technical variability (standard deviation) among replicates. Nucleic acid carriers are additives that enhance the yield of RNA isolation, which is particularly helpful in biological samples with low-concentration RNAs. We evaluated two different carriers, glycogen and bacteriophage MS2 RNA. Both MS2 RNA and glycogen carriers enhanced the RNA yield (Suppl . Table 1) , with MS2 RNA carrier slightly increasing technical background levels (Table 1 ). Next, we tested the consistency of each RNA isolation method. Four technical replicate isolations were carried out and TLDA array qPCRs were performed. All three tested methods gave high consistency and there was no statistically significant difference among the isolation methods tested although some trends were noted (Fig. 2a, Table 2 ). TRIzol isolation seemed to perform better as judged by the trends for lower background (high Cq in background), higher ΔCq above background, and better consistency among replicate isolations (smaller STDEV). When comparing qPCR Cq from different isolation methods, they generally agreed with each other, but were far from perfect (Fig. 2b) . From our data, it is clearly important to use one selected method consistently throughout a group of samples. On the other hand, when validating the results, it may be necessary to use a different approach, to avoid the inherent bias or false positives/negatives generated from the same isolation and detection systems.
In summary, the different methods appear to each have separate strengths and weaknesses (Table 3) . Overall, TRIzol LS provided slightly more consistent results but it involves a phenol/chloroform step and is technically challenging to obtain a Bclean^prep with that method. By contrast, miRCURY stands out for its easy and fast isolation procedure, good quality/quantity RNA, and a lack of organic solvent step in the process. We selected the miRCURY method with MS2 RNA carrier for further studies.
Preamplification Increases the Sensitivity and Uniformity of CSF miRNA Detection
We employed TaqMan® miRNA single-tube assays and TLDA panel to assess CSF miRNAs. Mindful of the challenge of combining both high technical sensitivity and low sampleto-sample variability, TaqMan® assays were tested with or without preamplification. Preamplification is an intermediate step after reverse transcription and before qPCR in which cDNA can be enriched over several orders of magnitude, theoretically without disturbing the relative expression of the different miRNAs (Suppl. Fig. 1 and [28] ). For detecting minute quantities of miRNA, preamplification greatly enhances the detection power of qPCR and data uniformity [28] . As showed in Fig. 3 , Cq of most miRNAs in the miR-15/107 TLDA panel fell to the background levels without preamplification. In contrast, preamplification improved detection sensitivity by several Cq values. Thus, for most of the miRNA species, preamplification is a necessary step when assessing CSF RNA using RT-qPCR.
CSF miRNA Exploratory Profiling Using TaqMan® Array Human MicroRNA A+B Cards Set v3.0
In order to better control technical variables and to assess the repertoire of miRNAs detectable with TaqMan® RT-qPCR assays in CSF, we ran a set of discovery (exploratory) profiling arrays using clinical CSF samples from four controls and four AD patients. Total RNA was extracted from CSF using Exiqon's miRCURY™ RNA Isolation Kit (Biofluids). MS2 RNA was used as additive and C. elegans Cel-miR-39 was spiked in to monitor the isolation efficiency. TaqMan® RTqPCR of Cel-miR-39 using the same volume (3 μl) of isolated RNAs gave similar Cq values across eight isolates with a standard deviation of 0.2 (Suppl. Table 2 ), indicating a consistent RNA isolation of all CSF samples. This was also evident by NanoDrop estimation of RNA concentrations. In the TaqMan® RT-qPCR miRNA results, a miRNA with Cq equal to or more than 35 was considered as undetectable. A miRNA was determined to be detectable in CSF if it was present in more than three arrays (out of eight). Using this cutoff, 130 and 63 miRNAs were detected in Card A and Card B, respectively. There was a small but statistically significant difference in median Cq of miRNA expression between the control and AD groups (Fig. 4) . Total miRNA content (represented by total Cq values) was also less abundant in AD group (higher Cq value). However, most individual miRNAs were not expressed differently between the samples (using the criterion of fold change ≥ 2, p ≤ 0.05), with the important caveat of the small sample size (Suppl. Excel file 1).
Most abundant miRNAs in CSF were identified by ranking average Cq values of all samples. The most abundant miRNAs (Table 4) included miR-204, miR-1274B, miR-16, miR-146a, miR-150, miR-223, miR-17, and miR-21 as described previously [13, 19] . The complete list of all detectable miRNAs can be found in supplemental Excel file 2.
The exploratory profiling also enabled us to select potential CSF-specific Bhousekeeping^miRNAs for data normalization. Table 5 shows miRNAs displaying relatively constant levels across both the control and AD groups and within the group as judged by their smaller standard deviations.
A CSF-miRNA Panel to Study miRNAs in the Context of Alzheimer's Disease
We chose customized TaqMan® miRNA RT-qPCR lowdensity array format 48 (Life Technologies) as the platform for studying CSF miRNAs relevant to AD. This PCR-based expression platform can simultaneously analyze eight samples and accommodate a total of 47 miRNAs plus one mandatory control (U6) per sample. The following criteria were used to select miRNAs for the panel (Table 6 ): (1) miRNA is detectable in CSF based on our profiling and existing literature; (2) miRNA was previously associated with AD (in tissue or CSF or both) or other neurodegenerative pathology; (3) miRNA is predicted to target genes critical to AD pathways (e.g., MAPTau, BACE1); (4) miRNA belongs to miR-15/107 or miR-29 family which are hypothesized to be perturbed and/or involved in neurodegenerative diseases; (5) miRNA is particularly brain-enriched; (6) miRNA is a potential normalizer (CSF housekeeping miRNAs); (7) Bcontamination^controls; and (8) ubiquitously expressed RNA species. MiRNAs that meet at least one of the above criteria were selected for the panel. These miRNAs plus U6 were custom-made into a low-density array card, and primers for RT and preamplification were prepared by Life Technologies® company.
Performance of CSF-miRNA Panel
To test the performance of the CSF-miRNA panel, the eight CSF samples that were used for profiling previously (four 1 miRNA is detectable in CSF based on our profiling and existing literature, 2 miRNA was previously associated with AD (in tissue or CSF or both) or other neurodegenerative pathology, 3 miRNA is predicted to target genes critical to AD pathways (e.g., MAPTau, BACE1), 4 miRNA belongs to miR-15/107 or miR-29 family which are hypothesized to be perturbed and/or involved in neurodegenerative diseases, 5 miRNA is particularly brain-enriched, 6 miRNA is a potential normalizer (CSF housekeeping miRNAs), 7 contamination controls, 8 ubiquitously expressed RNA species, ND not detected ADs, four controls) were tested using the novel platform. The CSF-miRNA panel TLDA analysis generated comparable Cq values as that of the inventory TaqMan® array cards. The panel seemed to be more sensitive as the overall average Cq was 2.4 lower than that of the inventory cards (Suppl. Table 3 ). There was a generally good correlation of miRNAs detected by both methods as indicated by Pearson correlation coefficient R squared (R 2 ) (Fig. 5 , Suppl. Table 3 ). However, several miRNAs showed a discrepancy which could be a result of a difference in primer pool size. Furthermore, primer interaction was observed with the custom-made CSF-miRNA panels (data not shown).
Detection of Tissue miRNAs Using CSF-miRNA Panel
RNA samples derived from the human hippocampus (two cases), cerebellum (two cases), and choroid plexus (four cases) and snap-frozen at autopsy and clinical blood drawn in a clinic and then frozen (two cases) were subjected to CSFmiRNA panel TLDA analysis. Although total RNA is much more abundant in tissue compared with that in CSF and it does not require preamplification to obtain a good readout data from these tissue samples, the RT-qPCR analyses followed the same procedure as that for CSF including the preamplification step to maintain the technical consistency. Most miRNAs in the CSF-miRNA panels were detected in brain tissues and blood samples. As expected, brain-specific or enriched miRNAs in the CSF panel, such as miR-124a, miR-9, and miR-125a, were not detected or with very low levels in the blood samples (Suppl. file 3). Several miRNAs displayed similar expression patterns in CSF and the choroid plexus (Suppl. file 3). For example, miR-1298 was detected in CSF and the choroid plexus, but not detected in the blood and cerebellum and was very low in the hippocampus; miR-34b and miR-34c also had higher expression levels in CSF and the choroid plexus than those in other tested tissues. Neuronal enriched miR-124a has a very low level in both CSF and the choroid plexus, as well as in the blood samples as expected. Several inflammatory/immunity-related miRNAs, such as miR-21, miR-223, miR-150, miR-155, miR-146a, miR-142-5p, and miR-142-3p, were all detected in tested brain tissues, but had relatively high levels in CSF and the choroid plexus. In addition, miR-204 and miR-1274B seemed to have higher levels in all brain tissues including CSF. Hierarchical clustering (Pearson's distance-Average Linkage) demonstrated that among the tested tissues, CSF miRNAs are clustered closely to the choroid plexus (Fig. 6 ) indicating a strong relationship to the organ that generates CSF. Correlation coefficient (R 2 ) of miRNA expression pattern between CSF and various tissues (Fig. 7) also indicated a close correlation (R 2 = 0.4567) between CSF and choroid plexus miRNA expression. A comparison of all the correlations between CSF and tissues showed that the correlation between miRNAs profiled in CSF and the choroid plexus were statistically significant (p = 0.019) [27] . The close correlation of CSF miRNA profile with the choroid plexus miRNA profile was further confirmed in a separate experiment which was carried out retrospectively after the initial evaluations. Using different CSF and tissue samples (Suppl. Fig. 3 , Suppl. file 4), it was demonstrated that the CSF miRNA profile had a much stronger correlation coefficient with that of the choroid plexus (R 2 = 0.5694) than with that of the cerebellum (R 2 = 0.1583). The difference between these two correlations was statistically significant (p = 0.0005) [27] . 
Discussion
Our study introduces a novel miRNA expression profiling platform designed for relatively efficient use in the context of CSF miRNA profiling. We recommend a technical pipeline that includes preanalytical parameters, normalization, and expression profile optimization. The TLDA returns results that are particularly tailored for the study of CSF miRNAs. We found for the first time that CSF miRNA profile is relatively closely correlated with the profile of miRNAs in the choroid plexus, in comparison to the samples of the hippocampus or cerebellum or blood that we evaluated. Since the TLDA is sensitive and characterized by relatively low technical variability and queries miRNAs that previously were shown to be relevant to neurodegenerative diseases, it could provide a robust platform for CSF analyses in conditions such as AD.
There are potential limitations to the present study. We underscore that there is no perfect miRNA profiling technique-because of the low levels of RNA in the CSF, there is a necessary tradeoff of sensitivity and technical variability. We previously have reported some of the technical differences that can be seen when data from different profiling platforms are compared [22, 29, 30] . Further, the use of TLDA cards lacks the ability of some other methods (such as RNA-Seq) to has-miR-125b has-miR-30a-3p has-miR-30e-3p has-miR-497 has-miR-204 has-miR-34a has-miR-29a has-miR-124a has-miR-107 has-miR-1274 has-miR-1298 has-miR-34b has-miR-29b has-miR-34c has-miR-21 has-miR-27a has-miR-132 has-let-7c has-miR-181a has-miR-29c has-miR-9 has-miR-30b has-miR-30c has-let-7a has-let-7f has-let-7b has-miR-195 has-miR-30d has-miR-30a-5p has-miR-142-5p has-miR-15a has-miR-155 has-miR-146a has-miR-150 has-miR-142-3p has-miR-19b has-miR-223 has-miR-451 has-miR-20a has-miR-16 has-miR-15b has-miR-106a has-miR-17 has-miR-146b has-miR-24 has-miR-103 U6 snRNA [13] [14] [15] [16] [17] [18] [19] , providing incentive for the field to achieve a standardized approach. Among the available miRNA profiling platforms, RTqPCR is relatively sensitive and economically viable. This method is particularly useful when the RNA input is limited, such as in the case of CSF RNA. There are two distinct miRNA RT-qPCR platforms currently widely used in the f i e l d . Ta q M a n ® m i R N A RT-q P C R a s s a y ( L i f e Technologies) employs a sequence-specific stem-loop RT primer to generate miRNA cDNA template followed by qPCR using sequence-specific primers and probes for quantification. Another type of platform uses a universal tailing and reverse transcription reaction followed by qPCR with sequence-specific PCR primers. The first method proves to be more specific while the latter is more sensitive, but less specific [31] . We chose TaqMan® miRNA RT-qPCR assay (Life Technologies) as our detection platform for its high specificity. Here, we reported results using TaqMan® Array Human MicroRNA A and B cards to profile eight clinical (four controls and four ADs) CSF miRNAs.
Our qPCR array profiling detected 193 miRNAs,~25% of miRNA species spotted on A and B cards (which tested a total 766 miRNAs). This is fewer than the detectable miRNAs obtained by Denk and the colleagues who profiled CSF miRNA using similar TaqMan® RT-qPCR-based OpenArray platform [19] which can profile more miRNAs at once (1178 miRNAs of OpenArray vs 766 of miRNA array Card A and B combined). However, most of the detectable miRNA in our profiling were also detected in OpenArray platform. The main purpose of this profiling was to provide necessary information with regard to detectability, abundance, and potential normalizers for the design of an optimized CSFmiRNA panel. Among the detectable miRNAs, several miRNAs, such as miR-1274B, miR-30b, and miR-30c, showed little variation from case to case and were each relatively abundant in CSF (Cq less than 30). These miRNAs were identified as potential normalizers in the panel. Notably, miR-1274B was also suggested as a potential normalizer by Denk et al. [19] .
We conclude that TLDA-based PCR assays provide a relatively robust and sensitive platform for CSF miRNA analyses. Most prior studies have focused on Bendpoints^rather than optimizing technical parameters. Here, we evaluated separate RNA isolation techniques and RNA carriers. The TLDA panel we propose incorporates the miRNAs highlighted as potentially important by prior studies and provides a context for further study. This constitutes a relatively high throughput ) of two data sets were obtained by linear regression assay that enables potential study design with greater numbers of clinical controls-including cognitively intact individuals with and without pathologic changes, as well as dementia controls with a variety of different conditions reflecting the common brain diseases of aging. Finally, we found it interesting that the miRNA profile of CSF more closely resembled (among the samples tested) those of the choroid plexus than those of either brain tissues or blood. MiRNAs are very powerful and promiscuous agents that regulate global gene expression. Our findings raise the provocative hypothesis that the choroid plexus can influence CNS cells via secretion of miRNAs into the CSF, a mechanism that could contribute to both healthy and diseased states in the brain.
